First Trust Advisors LP Takes $1.46 Million Position in Alumis Inc. $ALMS

First Trust Advisors LP purchased a new position in Alumis Inc. (NASDAQ:ALMS) in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 66,099 shares of the company’s stock, valued at approximately $1,456,000. First Trust Advisors LP owned approximately 0.05% of Alumis at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Ieq Capital LLC boosted its stake in Alumis by 4.1% in the fourth quarter. Ieq Capital LLC now owns 17,421 shares of the company’s stock worth $170,000 after buying an additional 690 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Alumis by 26.1% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,724 shares of the company’s stock worth $46,000 after purchasing an additional 979 shares during the last quarter. Strs Ohio raised its position in Alumis by 300.0% during the 1st quarter. Strs Ohio now owns 2,000 shares of the company’s stock valued at $44,000 after purchasing an additional 1,500 shares during the last quarter. ProShare Advisors LLC lifted its holdings in Alumis by 12.4% in the 4th quarter. ProShare Advisors LLC now owns 14,627 shares of the company’s stock worth $143,000 after buying an additional 1,618 shares during the period. Finally, KBC Group NV bought a new position in shares of Alumis during the first quarter valued at approximately $42,000.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on ALMS shares. HC Wainwright reiterated a “neutral” rating and issued a $25.00 price target on shares of Alumis in a report on Monday, August 3rd. Wall Street Zen lowered shares of Alumis from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Morgan Stanley reaffirmed an “overweight” rating and issued a $39.00 target price on shares of Alumis in a research report on Friday, May 15th. Guggenheim boosted their price target on shares of Alumis from $32.00 to $34.00 and gave the company a “buy” rating in a research report on Friday, May 15th. Finally, Wells Fargo & Company increased their price target on shares of Alumis from $49.00 to $51.00 and gave the stock an “overweight” rating in a research note on Friday, May 15th. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $40.30.

Alumis Stock Performance

Shares of NASDAQ ALMS opened at $27.60 on Monday. The company has a market cap of $3.52 billion, a PE ratio of -13.94 and a beta of -0.69. Alumis Inc. has a 52-week low of $3.76 and a 52-week high of $31.35. The firm’s 50 day moving average price is $25.62 and its 200-day moving average price is $25.27.

Alumis (NASDAQ:ALMS) last posted its earnings results on Thursday, May 14th. The company reported ($0.74) EPS for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.01). Alumis had a negative return on equity of 88.79% and a negative net margin of 2,825.70%.The business had revenue of $1.74 million during the quarter, compared to the consensus estimate of $2.10 million. On average, analysts forecast that Alumis Inc. will post -2.87 earnings per share for the current fiscal year.

Insider Transactions at Alumis

In other news, insider David M. Goldstein sold 2,596 shares of the business’s stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $26.37, for a total transaction of $68,456.52. Following the completion of the transaction, the insider directly owned 30,970 shares of the company’s stock, valued at $816,678.90. The trade was a 7.73% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Mark Christopher Bradley sold 2,572 shares of the stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $26.37, for a total transaction of $67,823.64. Following the transaction, the insider owned 48,533 shares in the company, valued at approximately $1,279,815.21. This trade represents a 5.03% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 19,953 shares of company stock valued at $534,311. Company insiders own 33.70% of the company’s stock.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.